The proportion of patients with solid tumors who had neutralizing antibodies against the omicron variant rose from 37% after 2 vaccine doses to 90% after 3 doses.
Andrea S. Blevins Primeau, PhD, MBA
Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.
